Аннотация
Сифилис – инфекционное заболевание человека, вызываемое Treponema pallidum, которое передаётся половым путём и относится к группе социально-значимых заболеваний. Во многих странах, включая Российскую Федерацию, отмечено резкое увеличение случаев сифилиса. Известно, что рандомизированные контролируемые исследования антибиотикорезистентности T. pallidum не применяются в связи с невозможностью культивирования патогена на искусственных питательных средах. В обзоре рассмотрены современные схемы терапии сифилиса с использованием препаратов группы пенициллина и альтернативных антибактериальных препаратов. Описана система длительного культивирования T. pallidum in vitro, которая создаёт условия для формирования доказательного подхода при поиске альтернативных антибактериальных препаратов для лечения сифилиса.
Список литературы
1. WHO. The global health observatory. Data on Syphilis. 2020-07-21. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/data-on-syphilis 2020-07-21.
2. WHO. New study highlights unacceptably high global prevalence of syphilis among men who have sex with men. News 9 July 2021. https://www.who.int/news/item/09-07-2021-new-study-highlightsunacceptably-high-global-prevalence-of-syphilis-among-menwho-have-sex-with-men.
3. Kubanov A.A., Bogdanova E.V. Perfomance results of medical organizations providing medical care in the field of dermatovenerology in 2019 – 2021 in the Russian Federation. Vestnik Dermatologii i Venerologii. 2022; 98(5): 18–33. (in Russian)
4. Stamm L.V. Syphilis: antibiotic treatment and resistance. Epidemiol. Infect. 2015; 143(8): 1567-74.
5. Krasnosel’skikh T.V., Sokolovskiy E.V. Current standards for syphilis treatment: comparing the russian and foreign guidelines (part II). Vestnik Dermatologii i Venerologii. 2015; 2: 23-40. (in Russian)
6. Nurse-Findlay S., Taylor Melany M., Savage M., Maeve B. M., Saliyou S., Lavayen M., et al. Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: an evaluation from multi-country surveys and stakeholder interviews. Plos One. 2017; 14(12):e1002473.
7. Albin S., Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. Allergy Asthma Proc. 2014; 35 (6): 489-94.
8. Arando M., Fernandez-Naval C., Mota-Foix M., Alvarez A., Armegol P., Barberá M.J. et al. The Jarisch-Herxheimer reaction in syphilis: could molecular typing help to understand it better? J.Eur. Acad. Dermatol. Venereol. 2018; 32: 1791–5.
9. Janier M., Unemo M., Dupin N., Tiplica G.S., Potocnik M., Patel R. 2020 European guideline on the management of syphilis. J. Eur. Acad. Dermatol. Venereol. 2021; 35 (3): 574-88.
10. Katunin G.L., Plakhova K.I., Abuduev N.K., Vasil’ev M.M. Ceftriaxone treatment of syphilis. Vestnik dermatologii i venerologii. 2021; 97(2): 23-31. (in Russian)
11. Stribuk P.V., Loseva O.K., Yudakova V.M. The comparative effectiveness of treatment of late neurosyphilis with penicillin and ceftriaxone. Klinicheskaya Dermatologiya i Venerologiya. 2016; 15(1):18‑22. (in Russian)
12. Katz K.A., Klausner J.D. Azithromycin resistance in Treponema pallidum. Curr. Opin. Infect. Dis. 2008; 21 (1): 83—91.
13. Centers for Disease Control and Prevention.Brief report: Azithromycin treatment failures in syphilis infections – San Francisco,California, 2002-2003. MMWR Morb. Wkly Rep. 2004; 53 (9):197-8.
14. Mitchell S.J., Engelman J., Kent C.K., Lukehart S.A., Godornes C., Klausner J.D. Azithromycin resistant syphilis infection: San Francisco, California, 2000-2004. Clin. Infect. Dis. 2006; 42 (3): 337-45.
15. Lukehart S.A., Gordones C., Molini B.J., Sonnett P., Hopkins S., Mulcahy F. et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N. Engl. J. Med. 2004; 351 (2): 154—8.
16. Zhou P., Li K., Lu H., Gu X., Gong W., Tucker J.D. et al. Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai. Sex. Transm. Dis. 2010; 37 (11): 726—9.
17. Edmondson D.G., Hu B., Norris S.J. Long-term in vitro culture of the syphilis spirochete Treponema pallidum subsp. pallidum. MBio. 2018; 9(3):e01153–18 e01118.
18. Stamm L.V. Hope for new antibiotics for syphilis treatment. EBioMedicine. 2021; (66): 103320.
19. Haynes А.M., Giacani L., Mayans M.V. et al. Efficacy of linezolid on Treponema pallidum, the syphilis agent: a preclinical study. EBioMedicine. 2021; (65):103281.
20. Dryden M.S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J. Antimicrob. Chemother. 2011; 66(4): 7–15.
21. Deka R.K., Machius M., Norgard M.V., Tomchick D.R. Crystal structure of the 47-kDa lipoprotein of Treponema pallidum reveals a novel penicillin-binding protein. J. Biol. Chem. 2002; 277: 41857-64.
22. Obraztsova O.A., Aleynikova K.A., Obukhov A.P., Kubanov A.A., Deryabin D.G.Genetic antimicrobial resistance determinants and their prevalence in molecular subtypes of Treponema pallidum subsp. рallidum. Klinicheskaya mikrobiologiya i antimikrobnaya terapiya. 2018; 20 (3): 216-21. (in Russian)
23. Xiao H., Li Z., Li F., Wen J., Liu D., Du W. et al. Preliminary study of tetracycline resistance genes in Treponema pallidum. J. Glob. Antimicrob. Resist. 2017; (9):1-2.
24. Fernández-Naval C., Arando M., Espasa M., Antón A., FernándezHuerta M., Silgado A. et al. Enhanced molecular typing and macrolide and tetracycline-resistance mutations of Treponema pallidum in Barcelona. Future Microbiol. 2019; (14):1099-1108.
25. Mateˇjková P., Strouhal M., Smajs D., Norris S.J., Palzkill T., Petrosino J.F. et al. Complete genome sequence of Treponema pallidum ssp. pallidum strain SS14 determined with oligonucleotide arrays. BMC Microbiol. 2008; 8:76.
26. WHO. Guidelines for the treatment of Treponema pallidum(syphilis) 2016. Available at: https://www.who.int/publications/i/item/9789241549714.
27. Stamm L.V. Antibiotic resistance in Treponema pallidum subsp. pallidum, the syphilis agent. In: Embers M.E., eds. The Pathogenic Spirochetes: Strategies for Evasion of Host Immunity and Persistence. New-York: Springer Science+Business Media; 2012.
28. Mateˇjková P., Flasarová M., ZákouckáH., BořekM., KřemenováS, Arenberger P. et al. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in 23S rRNA gene of Treponema pallidum subsp. pallidum. Journal of Medical Microbiology. 2009; 58: 832–6.
29. Ghanem K.G, Workowski K.A. Management of adult syphilis. Clinical Infectious Diseases. 2011; 53 (3): 110–28.
30. Grimes M., Sharon S.K, Godornes B.C., Tantalo L.C., Roberts N., Bostick D. et al. Two mutations associated with macrolide resistance in Treponema pallidum: increasing prevalence and correlation with molecular strain type in Seattle, Washington. Sexually Transmitted Diseases. 2012; 39: 954–8.
31. The A2058G Prevalence Workgroup. Prevalence of the 23S rRNA A2058G point mutation and molecular subtypes in Treponema pallidum in the United States, 2007– 2009. Sexually Transmitted Diseases. 2012; 39: 794–8.
32. Li Z., Hou J., Zheng R., Wen J., Liu R., Liu D. et al. Two mutations associated with macrolide resistance in Treponema pallidum in Shandong, China. Journal of Clinical Microbiology. 2013; 51:4270–1.
33. Muldoon E.G., Walsh A., Crowley B., Mulcahy F. et al. Treponema pallidum azithromycin resistance in Dublin, Ireland. Sexually Transmitted Diseases. 2012; 39: 784–6.
34. Read P., Jeoffreys N., Tagg K., GuyR.J., Gilbert G.L., Donovan B. et al. Azithromycin-resistant syphilis-causing strains in Sydney, Australia: prevalence and risk factors. Journal of Clinical Microbiology. 2014; 52: 2776–81.
35. Tipple C., McClure M.O., Taylor G.P. High prevalence of macrolide resistant Treponema pallidum strains in a London centre. Sexually Transmitted Infections. 2011; 87: 486–8.
36. Chen C.Y., Chi K-H., Pillay A., Nachamkin E., Su J.R., Ballard R.C. et al. Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a TaqMan real-time multiplex PCR assay. Journal of Clinical Microbiology. 2013; 51: 908–13.
37. Van Damme K., Behets F., Ravelomanana N., Godornes C., Khan M., Randrianasolo B. et al. Evaluation of azithromycin resistance in Treponema pallidum specimens from Madagascar. Sexually Transmitted Diseases. 2009; 36: 775–6.
38. Müller E.E., Paz-Bailey G., Lewis D.A. Macrolide resistance testing and molecular subtyping of Treponema pallidum strains from southern Africa. Sexually Transmitted Infections. 2012; 88: 470–4.
39. Wu H., Chang S.Y., Lee N.Y., Huang W.C., Wu B.R., Yang C.J. et al. Evaluation of macrolide resistance and enhanced molecular typing of Treponema pallidum in patients with syphilis in Taiwan: a prospective multicenter study. Journal of Clinical Microbiology. 2012; 50: 2299–2304.
40. Wu B.R., Yang C.J., Tsai M.S., Lee K.Y., Lee N.Y., Huang W.C. et al. Multicentre surveillance of prevalence of the 23S rRNA A2058G and A2059G point mutations and molecular subtypes of Treponema pallidum in Taiwan, 2009–2013. Clinical Microbiology Infection. 2014; 20(8): 802-7.
41. Khairullin R., Vorobyev D., Obukhov A., Kuular U-H., Kubanova A., Kubanov A. et al. Syphilis epidemiology in 1994-2013, molecular epidemiological strain typing and determination of
macrolide resistance in Treponema pallidum in 2013- 2014 in Tuva Republic, Russia. APMIS. 2016; 124(7): 695-702.